Harbeck N - Search Results

1

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.

Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Konecny GE, Untch M, Kurbacher C; AGO Breast Study Group (AGO-B). Möbus V, et al. Among authors: harbeck n. Ann Oncol. 2018 Jan 1;29(1):178-185. doi: 10.1093/annonc/mdx690. Ann Oncol. 2018. PMID: 29069370 Free article. Clinical Trial.

2

[Prognostic value of tumor cells in bone marrow in breast cancer].

Untch M, Nestle-Krämling C, Konecny G, Harbeck N, Funke I, Kimmig R, Hepp H. Untch M, et al. Among authors: harbeck n. Gynakol Geburtshilfliche Rundsch. 1993;33 Suppl 1:308-10. doi: 10.1159/000272278. Gynakol Geburtshilfliche Rundsch. 1993. PMID: 8118327 German. No abstract available.

3

[Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma].

Harbeck N, Dettmar P, Thomssen Ch, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H. Harbeck N, et al. Gynakol Geburtshilfliche Rundsch. 1995;35 Suppl 1:142-7. doi: 10.1159/000272586. Gynakol Geburtshilfliche Rundsch. 1995. PMID: 8672914 German.

4

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.

Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H, Höfler H. Dettmar P, et al. Among authors: harbeck n. Br J Cancer. 1997;75(10):1525-33. doi: 10.1038/bjc.1997.261. Br J Cancer. 1997. PMID: 9166949 Free PMC article.

5

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.

Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H. Schmitt M, et al. Among authors: harbeck n. Br J Cancer. 1997;76(3):306-11. doi: 10.1038/bjc.1997.383. Br J Cancer. 1997. PMID: 9252196 Free PMC article.

6

Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M. Thomssen C, et al. Among authors: harbeck n. Anticancer Res. 1998 May-Jun;18(3C):2173-80. Anticancer Res. 1998. PMID: 9703780

7

Prognostic impact of tumor biological factors on survival in node-negative breast cancer.

Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H, Schmitt M. Harbeck N, et al. Anticancer Res. 1998 May-Jun;18(3C):2187-97. Anticancer Res. 1998. PMID: 9703782

8

HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M. Harbeck N, et al. Int J Oncol. 1999 Apr;14(4):663-71. doi: 10.3892/ijo.14.4.663. Int J Oncol. 1999. PMID: 10087312

9

Thrombophilic state in breast cancer.

Schmitt M, Kuhn W, Harbeck N, Graeff H. Schmitt M, et al. Among authors: harbeck n. Semin Thromb Hemost. 1999;25(2):157-66. doi: 10.1055/s-2007-994917. Semin Thromb Hemost. 1999. PMID: 10357083 Review.

10

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.

Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Br J Cancer. 1999 May;80(3-4):419-26. doi: 10.1038/sj.bjc.6690373. Br J Cancer. 1999. PMID: 10408848 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

720 results

Search Page

Filters